NLRP3 Exploit Map¶
Black Hat Pen-Testing the Inflammatory Cascade
A mechanism map of vulnerabilities in the gout-relevant NLRP3 cascade. It separates seven chokepoints, evidence levels, tissue context, and the experiments needed to falsify candidate interventions. Named compounds are research candidates or established-care comparators, not a recommended stack.
The map represents gout-specific complement priming as CP0, separates NF-κB and ROS priming, separates IL-1 receptor blockade from active resolution, and treats neutrophil amplification and pyroptotic exit as distinct branches. See complement-c5a-gout.md and spm-resolution-pathway.md.
Species-gap caveat: Prefer human-cell potency when available and apply the cross-species standard in
chembl-cross-check.mdbefore translating rodent results.Tissue-paradox caveat (2026-07-13): In intestinal epithelium, NLRP3 signaling is linked to PDZK1/ABCG2 regulation in direct human-cell work. A systemically anti-inflammatory NLRP3 inhibitor could therefore have a different or even opposing effect on the intestinal urate-export gate. Do not score candidates only in macrophages. Pair IL-1β/ASC readouts with surface ABCG2 and transepithelial urate flux in validation experiment 1.35.
The NLRP3 Kill Chain¶
MSU crystals deposit in a joint → complement and other priming routes can engage:
╔══════════════════════════════════════════════════════════════════════════╗
║ CHOKEPOINT 0 — CRYSTAL-TRIGGERED COMPLEMENT PRIMING ║
║ MSU directly activates complement → C5a primes NLRP3 via ROS ║
║ ▲ C5aR1/C5 perturbations are research comparators, not gout therapy ║
║ ▲ Direct local C5a coverage remains an evidence and delivery gap ║
╚══════════════════════════════════════════════════════════════════════════╝
│
▼
╔══════════════════╗ ╔══════════════════╗ ╔══════════════════╗
║ CHOKEPOINT 1 ║────▶║ CHOKEPOINT 2 ║────▶║ CHOKEPOINT 3 ║
║ NF-κB PRIMING ║ ║ K⁺ EFFLUX / NLRP3║ ║ ASC SPECK ║
║ CP1a: TNFSF14 ║ ║ P2X7: one input ║ ║ ║
║ CP1b: C5a→ROS ║ ║ ║ ║ Assemble platform║
╚══════════════════╝ ╚══════════════════╝ ╚══════════════════╝
▲ Sulforaphane, EGCG ▲ BHB, Oridonin ▲ Colchicine
Curcumin, Berberine NAC, MitoQ, Tranilast Spermidine
KPV: gout conjecture Spermidine, HCQ
Repair leads separate Trehalose, Colchicine
│ │ │
▼ ▼ ▼
╔══════════════════╗ ╔══════════════════════════╗ ╔═══════════════════╗
║ CHOKEPOINT 4 ║────▶║ CHOKEPOINT 5 ║───▶║ CHOKEPOINT 6 ║
║ CASPASE-1 ║ ║ IL-1β / IL-18 OUTPUT ║ ║ NEUTROPHIL AMP + ║
║ ║ ║ CP5a: Receptor blockade ║ ║ PYROPTOTIC EXIT ║
║ Canonical execution║ ║ CP5b: ALX/FPR2 SPM ║ ║ CP6a: 5-LOX/LTB4 ║
║ ║ ║ resolution ║ ║ CP6b: GSDMD pore ║
╚══════════════════╝ ╚══════════════════════════╝ ╚═══════════════════╝
▲ VX-765 (research) ▲ Anakinra, Canakinumab ▲ Quercetin, AKBA
Rilonacept (CP5a) EPA→RvE1 (CP6a)
RvD1, MaR1 (CP5b) Disulfiram, DMF
RvD2: adjacent NSA (CP6b)
──────────────────────────────────────────────────────────────────────────────
UPSTREAM AXIS: Sustained urate lowering can reduce crystal substrate;
it must be tested separately from inflammatory blockade
──────────────────────────────────────────────────────────────────────────────
CP0 — Crystal-triggered complement priming¶
Mechanism: MSU crystal surface directly activates classical and alternative complement pathways → C3a and C5a anaphylatoxins generated → C5a binds C5aR1 on neutrophils and macrophages → ROS burst provides non-transcriptional NLRP3 priming (Signal 1), upstream of or parallel to NF-κB.
An et al. reported C5a-associated priming in human peripheral-blood mononuclear cells exposed to MSU crystals (In Vitro; PMID 25229885). Cumpelik et al. demonstrated a C5a-mediated priming route and its endogenous microvesicle brake in their gout model (Ann Rheum Dis 2016, PMID 26245757). Khameneh et al. linked MSU-associated complement activation to C5a, ROS, NLRP3 activity, and leukocyte recruitment in murine MSU peritonitis, with improvement under C5aR antagonism (Front Pharmacol 2017, PMID 28167912). These studies establish C5a as a plausible rapid priming route; they do not establish clinical dominance over TLR4, TNFSF14, or other inputs across human gout flares.
Evidence and intervention landscape at CP0: - Avacopan, zilucoplan, eculizumab, and other complement drugs — human evidence exists outside gout. Their distinct perturbations make them mechanistic comparators; none has established gout efficacy. - Direct C5a/C5aR1 discovery gap. The recorded searches did not retrieve a validated fermentable food-derived direct modulator; this is a bounded coverage result, not an empty-class claim. Omega-3 SPMs and vitamin-D-related signals concern indirect pathways and require their own mechanism-matched tests.
Local complement-regulator hypothesis: COMP-012 motivates testing a stalk-truncated DAF/CD55 SCR1–4 construct but does not establish protease survival because it used pLDDT confidence as accessibility. Correct folding, retained CCP-regulatory function, processing stability, tissue access, and suppression of submucosal-macrophage CP0 priming remain empirical gates. See H05. (Mechanistic Extrapolation)
C1-INH complement-entry hypothesis: comp-037 supplies a sequence-filter/pLDDT inventory and a kinetic-competition hypothesis, not a MODERATE protease verdict. Exact-configuration folding and luminal stability precede RCL kinetic competition, functional complement assays, and tissue-access testing. C1-INH and DAF remain independent mechanism candidates whose delivery routes are unranked. (Mechanistic Extrapolation.)
Upstream-CP0 natural-product axis: Houttuynia cordata polysaccharides remain an exact-material complement lead with their evidence and boundaries on the Houttuynia page. Helicteres benzofuran lignans remain a single-paper anchor pending independent matched-assay replication. C1-INH is a separate exact-configuration engineering question. Retired COMP-018 supplies no ranking among them.
C5aR1 natural-product discovery gap: No current qualified screen closes this chemical space. Retired COMP-014 supplies no absence evidence. A direct human-C5aR1 functional screen with exact identity, provenance, polarity, exposure, and counter-screen controls remains an open experiment; a no-hit would close only the tested library and assay regime.
Fungal NLRP3 search-frame sensitivity: Species-name, material-name, and traditional-pathology queries have surfaced unranked primary-study leads that mechanism-only database searches can miss. This does not establish a coverage census or a strongest species. Exact material-specific evidence and falsification tests belong on the medicinal-mushroom page.
Deep dive: complement-c5a-gout.md
CP1 — NF-κB Priming (Signal 1, transcriptional)¶
Mechanism: Transcriptional arm of inflammasome priming — upregulates NLRP3, pro-IL-1β, pro-IL-18 mRNA. Distinct from CP0 (non-transcriptional C5a→ROS priming) and from the K⁺ efflux activation step (CP2).
CP1 splits into two mechanistically distinct sub-branches. CP1a is the classical NF-κB transcriptional priming arm (where most of the stack's NF-κB inhibitors land, including the TNFSF14/LIGHT amplifier). CP1b is the non-transcriptional C5a→ROS priming pathway uncovered by Khameneh 2017, covered in complement-c5a-gout.md but cross-listed here because it is functionally "Signal 1" even though it bypasses NF-κB transcription.
2025 single-cell annotation: S100A8/A9-high CD14⁺ classical monocytes were a flare-associated population in the reported single-cell study (Alaswad et al. 2025 Ann Rheum Dis PMID 40023733). The association does not establish that this population drives the flare. Test S100A8/A9 perturbation and time order before assigning a causal role.
CP1a — TNFSF14 (LIGHT) Amplifier of NF-κB Priming¶
TNFSF14 (LIGHT) is an emerging gout-specific priming amplifier. TNFSF14 signals via HVEM → NF-κB → IL-6 + NLRP3 priming, and is elevated in gout patient serum. CERC-002 (anti-TNFSF14 mAb) provides a biologic comparator. See tnfsf14-gout-target.md for the evidence and clinical status.
CP1b — C5a → ROS → NLRP3 Priming (non-transcriptional)¶
Khameneh 2017 (PMID 28167912) linked C5aR1 signaling on phagocytes to a ROS-dependent NLRP3-priming route that did not require transcriptional upregulation in the tested system. This identifies a non-transcriptional route that must be compared with TLR4, TNFSF14, and other priming inputs in matched human gout-relevant systems. Full detail in complement-c5a-gout.md.
KPV Peptide¶
KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-MSH. Dalmasso et al. measured PepT1-related KPV transport and an NF-κB reporter effect in named intestinal epithelial and Jurkat-cell systems (In Vitro; PMID 18061177). Those observations do not establish IκB stabilization, direct NLRP3-assembly activity, an MSU response, synovial-macrophage uptake, or a gout delivery route.
KPV's gout relevance is a Research Conjecture: if a gout-relevant macrophage can accumulate exact KPV material, the peptide might change inflammatory priming. The discriminating experiment must measure KPV uptake, PepT1 attribution, NF-κB priming, NLRP3/ASC/caspase-1 output, viability, and free exposure under MSU challenge. See the bounded KPV evidence page.
Sulforaphane has gout-relevant pathway evidence in two source-pinned studies. Yang 2018 (Rheumatology (Oxford), PMID 29340626) reported reduced MSU-induced foot-pad swelling and neutrophil recruitment and used an air-pouch model to examine NLRP3-related readouts (Animal Model). Greaney 2015 (J Leukoc Biol, PMID 26269198) reported Nrf2-independent NLRP3-pathway effects in macrophages and an acute-gout peritonitis model (In Vitro + Animal Model). These two studies support a gout-relevant pathway experiment; they do not establish direct NLRP3 binding or human efficacy. See the inhibitor screen.
Sulforaphane exposure depends on glucoraphanin conversion by myrosinase. Preparation and formulation can therefore change measured exposure, but no food-preparation instruction follows from the animal and macrophage results. A gout-relevant study should quantify sulforaphane exposure and target engagement directly.
Curcumin suppresses NF-κB in experimental systems, but formulation strongly changes exposure. Piperine, lipid, nanoparticle, and micellar formulations are distinct pharmacokinetic objects; relative-bioavailability claims do not establish gout efficacy or a preferred formulation. Compare measured free exposure and target engagement rather than treating formulation availability as validation.
Exact RvD1 and MaR1 materials changed MSU inflammation in mouse models (Animal Model; PMIDs 35716378 and 37996809). RvD2 has adjacent macrophage and zymosan-peritonitis evidence, not direct gout evidence (PMID 29601102). EPA and DHA are precursors; they do not establish production or delivery of any named mediator. Identity, conversion, exposure, and mechanism must be measured separately.
The Nature Medicine experiments support BHB as an NLRP3 pathway modulator in urate-crystal-relevant systems. They do not establish direct binding, a fasting or ketone intervention, or an acute-flare protocol.
BHB reduced potassium-efflux and ASC-speck readouts in cited experimental systems and attenuated urate-crystal peritonitis in mice. These results support a CP2/CP3 mechanistic probe; they do not establish human exposure, a direct binding interaction, net urate effect, or a fasting or ketone intervention. In Vitro + Animal Model (PMID 25686106).
Ketone bodies can affect both NLRP3 and renal urate handling. A gout study must measure both axes across timing and tissue context; inflammasome activity alone cannot establish net benefit, prophylaxis, or an acute-flare protocol. See bhb-ketones.md.
Glucocorticoid Receptor (GR) Signaling — Endogenous Cortisol + Pharmacological Glucocorticoids¶
Mechanism (CP1 + CP2): GR is a ligand-activated transcription factor. Diaz-Jimenez et al. reported GR-dependent changes in inflammatory transcription, ACOD1-associated metabolism, and inflammasome readouts in their tested mouse and human-macrophage systems (FASEB J 2026, PMC12862736; Animal Model + In Vitro). The source supports a pathway contribution in those systems, not a universal transcriptional sequence or a proven metabolic cause of human gout flares.
Timing dependence: In the cited experimental system, priming before glucocorticoid exposure produced a different transcriptional and inflammasome response from co-treatment. Post-priming chromatin state is a candidate explanation. This assay result does not define clinical timing or prophylaxis.
Gout-relevant mechanistic data: In the cited study, myeloid-GR-knockout mice showed increased IL-1β and neutrophil influx six hours after MSU peritonitis, while RU-486 perturbation in human monocyte-derived macrophages changed related readouts. Animal Model + In Vitro. Together these support a GR-dependent pathway contribution in the tested systems; they do not define clinical timing or prove that the same causal step dominates a human flare.
Concentration dependence (Wu 2020, PMC7251469): Corticosterone produced directionally different NLRP3 readouts across the tested concentration range in LPS-primed macrophages. This is an in-vitro concentration-response result, not an explanation of human flare triggers or a dosing rule.
Endogenous engagement during untreated gout flare (Zhang 2023, PMC9989260): The study reported higher 24-hour urinary free cortisol during acute flare and cross-sectional associations with inflammatory and urate-related measures (Human Observational). The pattern is compatible with HPA activation during flare; it does not establish beneficial counter-regulation or causality.
Clinical boundary: glucocorticoids and IL-1 blockers engage different nodes and have different safety profiles. This map does not rank treatments. The inhaled mRNA–IL-1Ra concept remains unvalidated and cannot be inferred from anakinra.
Evidence tier on this page: In Vitro + Animal Model + human monocyte-derived macrophage evidence (PMC12862736, PMC7251469); Human Observational HPA-during-flare evidence (PMC9989260). Clinical gout comparator evidence for named glucocorticoids is maintained on the clinical pipeline, not inferred from these mechanistic studies.
Berberine has reported NF-κB, inflammasome-transcript, and microbiome effects. These are separate hypotheses: target-proximal activity, tissue exposure, community change, and gout outcome must be measured independently.
Berberine has been studied in SIBO and has separate NLRP3-pathway evidence. Evidence in one condition does not establish a shared intervention or gout benefit; microbiome and inflammasome effects must be tested separately.
Resveratrol activates SIRT1 and can change NF-κB-related readouts in experimental systems. Rapid metabolism limits free exposure. Different formulations and analogs are separate pharmacokinetic objects and require matched exposure, target-engagement, and safety testing.
Andrographolide from Andrographis paniculata has been reported to modify NF-κB p50 at Cys62 and reduce DNA binding. Traditional use does not establish gout exposure, efficacy, or safety.
Parthenolide from Tanacetum parthenium has reported IKKβ and p65 effects. DMAPT is a research derivative with different exposure properties. Neither traditional use nor solubility establishes a gout intervention.
Thymulin (zinc-dependent thymic nonapeptide) reduced NF-κB and cytokine readouts in aged mouse myeloid cells and human PBMCs in the cited work. The reported age dependence and absence of an MSU-crystal experiment make gout translation a mechanistic extrapolation. Test aged and younger cells without preselecting a human demographic or treatment use. See thymulin.md. In Vitro + Animal Model; Mechanistic Extrapolation for gout.
BPC-157 and TB-500 are research candidates with adjacent-model NF-κB, JNK/p38, autophagy, or cytoprotection signals. Neither route, exposure, nor gout efficacy is established by those models.
BPC-157 has adjacent-model cytoprotection and nitric-oxide-pathway signals. Its relevance to joint damage or macrophage state in gout remains untested.
EGCG inhibits IKK-related signaling and suppresses NF-κB in experimental systems; it also has reported effects at CP4 and CP5. Food and concentrated-extract exposures are not interchangeable, and this map does not specify a human dose.
Boswellia (AKBA) — AKBA is retained as an unqualified CP6a lead, not as a source-pinned result. Reverify the exact material, primary 5-LOX assay, free exposure, and selectivity before using it as a comparator; the current compact ChEMBL receipt supplies no target census or cross-target rank.
Houttuynia cordata polysaccharides — Li 2025 found that both defined HCPM and crude HCP reduced intestinal NLRP3, cleaved caspase-1, IL-1β, and IL-18 in H1N1–MRSA coinfection mice (Animal Model; PMID 40654358). Cheng 2014 found that a different 60 kDa HCP-2 material increased IL-1β in naïve human PBMCs through a TLR4-sensitive response (In Vitro; PMID 24528726). These materials and contexts are not interchangeable. The current Houttuynia evidence page retains no source-verified isolated-polysaccharide MSU/gout experiment; that is a corpus boundary, not a universal absence claim. Validation §1.30 tests direct macrophage directionality; COMP-040 independently tests complement.
Theaflavins (TF1/TF2A/TF2B/TF3, black-tea polyphenols) — Chen 2023 (PMID 37221235) reported concentration-dependent inhibition of NLRP3-related readouts in LPS-primed macrophages stimulated with MSU crystals and attenuation of MSU-induced mouse peritonitis. Reported NLRP3–NEK7, TNFSF14/HVEM, and renal-transporter effects justify a multi-readout experiment; they do not establish additivity with EGCG or a human gout effect. See theaflavins.md. In Vitro + Animal Model.
Vitamin D/VDR signaling can alter NF-κB-related transcription, but serum targets, supplementation, and gout outcomes require separate clinical evidence.
Quercetin has reported NF-κB, mast-cell, xanthine-oxidase, and 5-LOX activity. Formulation changes exposure; neither a formulation nor a supplement dose is selected by this mechanism map.
Quercetin's NLRP3 framing rests on functional inflammasome readouts rather than a source-verified direct NLRP3-binding measurement, so it is an NLRP3 pathway modulator. A separate primary record reports 5-LOX IC50 = 300 nM (J Med Chem 1991; PMID 2066989; In Vitro), motivating an LTB4-pathway experiment. Cross-assay potency ratios do not rank the mechanisms or establish a gout effect.
A. oryzae provides a candidate expression toolkit, but the parent organism's food-use history does not establish the safety or regulatory status of an engineered strain or recombinant payload. Payload relevance, delivered exposure, construct behavior, containment, and product-specific safety must be tested directly. Any proposal to add UOX also remains conditional on validation §1.33 and §1.36; chassis convenience cannot bypass those gates.
CP2 — K⁺ Efflux / NLRP3 Activation (Signal 2)¶
Mechanism: The activation step. MSU crystal phagocytosis can engage purinergic signaling, K⁺ efflux, mitochondrial ROS, lysosomal damage, and NLRP3–NEK7 association. These inputs can contribute in a system-dependent way; this map does not claim that each is independently necessary or sufficient in every gout-relevant context.
K⁺ efflux mechanism annotation: MSU-associated inflammasome activation can involve purinergic signaling and K⁺ efflux. Leung et al. 2015 (PMID 26228647) reviews microtubule and P2X7-related contributions to colchicine pharmacology; that review does not make every gout effect a direct P2X7-pore mechanism. See colchicine.md for the evidence boundary. Taurine remains an unranked retrieval lead; this page retains no source-pinned potassium-efflux claim for it.
Oridonin¶
Mechanism: Reported covalent modification of Cys279 in the NLRP3 NACHT domain, with NLRP3–NEK7 and inflammasome readouts in experimental systems (PMID 29959312; In Vitro + Animal Model).
Oridonin is an ent-kaurane diterpenoid reported to covalently modify NLRP3 Cys279 and block the NLRP3–NEK7 interaction.
The 2018 study reported caspase-1, IL-1β, and pyroptosis effects in cell-free and mouse-macrophage assays, with NLRC4 and AIM2 comparators. Human cellular potency and selectivity require separate measurement.
The current source-pinned record does not establish a human-cell concentration anchor. Any biochemical, mouse-cell, or later human-cell value must be reverified in its own assay before use. See the inhibitor screen.
Reported Nrf2 and NF-κB effects justify additional readouts but do not establish multi-chokepoint efficacy.
Celastrol — Mechanistic Comparator, Not an Intervention¶
Celastrol (tripterine), a quinone-methide triterpenoid from Tripterygium wilfordii, adds a distinct CP2 control point to the map: NLRP3 deubiquitination state. Yan et al. 2021 reported that celastrol suppressed caspase-1 processing and IL-1β maturation in human THP-1 cells and mouse bone-marrow-derived macrophages, then attenuated inflammation in an MSU-induced gouty-arthritis mouse model. The proposed mechanism is interference with BRCC3-dependent K63 deubiquitination of NLRP3, preserving an assembly-incompetent state and preventing formation of the NLRP3–ASC–pro-caspase-1 complex (In Vitro + Animal Model; Phytomedicine 2021, PMID 33130474, DOI 10.1016/j.phymed.2020.153398).
Evidence boundary: this study supports celastrol as an NLRP3 pathway modulator with gout-specific animal evidence, not as a clean direct human-NLRP3 binder. Celastrol's electrophilic quinone-methide reacts with cysteine thiols across many proteins; proteome-wide profiling identified broad reversible covalent target engagement rather than single-target selectivity (Molecular BioSystems 2017, DOI 10.1039/C6MB00691D). Preclinical inhibition of cardiac Kir2.1/hERG channels (PMID 16407206) and impairment of B-cell and erythrocyte development in mice (PMID 22545133) exclude it from the OE intervention pipeline on current evidence. A dated ClinicalTrials.gov check on 2026-07-15 found no posted results for the two named studies of isolated celastrol (NCT05494112; NCT05413226); current status requires a fresh registry check. OE use: retain celastrol as evidence that NLRP3 deubiquitination is a druggable CP2 sub-node and as a cautionary medicinal-chemistry scaffold; do not place it in the stack, intervention-coverage table, or engineering pipeline.
MSU phagocytosis can generate mitochondrial ROS and disrupt lysosomes, providing two experimentally separable NLRP3 inputs. Candidate controls include:
- NAC/GlyNAC and alpha-lipoic acid: glutathione-axis perturbations; gout-relevant exposure and compartmental target engagement remain open.
- MitoQ: mitochondria-targeted redox perturbation; compare directly with an untargeted antioxidant at matched intracellular effect.
- MnTBAP and EUK-134: research SOD-mimetic controls.
- Tranilast: Direct NACHT-domain mechanism in vitro (PMID 29531021) and human exposure in other indications. Any gout-animal or clinical effect requires a separate source; gout efficacy remains unestablished.
- Spermidine, trehalose, and rapamycin: distinct autophagy-related perturbations. Their effects on autophagy do not establish a gout regimen.
- Hydroxychloroquine, procyanidin B2, and desferrioxamine: lysosomal or crystal-interface hypotheses requiring direct MSU/macrophage comparison and compound-specific safety review.
These are experimental candidates, not consumer or off-label treatment instructions. Advance them by measured exposure, mechanistic readouts, and a prespecified gout-relevant falsification rule.
MCC950 (CRID3) is a mechanistic NLRP3 comparator with reported NACHT/ATPase and inflammasome effects. The current compact ChEMBL receipt cannot support a synonym-complete retrieval claim or independently validate a potency value. Use the exact primary assay and product-specific safety record when defining its control role. (Source trail: NLRP3 inhibitor screen.)
Dapansutrile (OLT1177) has a published Phase 2a gout study (PMID 33005902). That trial supplies clinical evidence for the compound and protocol studied; it does not validate other NLRP3 candidates or imply an access or development timeline. See gout-clinical-pipeline.md.
Dapansutrile translation warning: Separate mouse and human cellular studies report different IC50 values under different assay contexts. Because species, cell system, stimulation, and protocol all change together, their numerical ratio is not an isolated species effect. Use the records to motivate a matched species-bridging assay, not to infer a human dose or explain the clinical result. In Vitro + Clinical Trial; source trail: NLRP3 inhibitor screen.
CP3 — ASC Speck Assembly¶
Mechanism: ASC (encoded by PYCARD) oligomerizes via PYD-PYD and CARD-CARD interactions into a single cytoplasmic "speck" — the signaling platform that recruits and activates caspase-1. Transport of ASC from mitochondria to ER-localized NLRP3 is microtubule-dependent.
Colchicine — The Established Exploit¶
Mechanism: Binds tubulin and disrupts microtubule-dependent processes. Experimental literature links this to neutrophil functions and inflammasome-assembly readouts; P2X7-related effects are a separate reported contribution (reviewed in PMID 26228647), not a complete explanation of colchicine efficacy. See colchicine.md.
Colchicine is an established gout therapy with multiple microtubule-dependent effects. Experimental systems support effects on neutrophil recruitment, crystal handling, mediator release, and ASC-speck assembly. The relative contribution of each mechanism to a human flare is not resolved, so this map uses colchicine as a clinical comparator rather than assigning a single exact reason for efficacy.
IC100 is an anti-ASC antibody intended to block speck oligomerization. It is a target-class comparator; development status or availability does not establish gout efficacy or sufficiency of ASC blockade.
BHB reduces ASC oligomerization and speck formation in cited experimental systems. This is a CP3 readout, not evidence of broader efficacy.
PYCARD modulation: ASC is encoded by the PYCARD gene. Epigenetic regulation of PYCARD is a mechanistic lead, but the current source set does not establish that sulforaphane or another candidate produces a gout-relevant PYCARD-mediated effect. Advance this only through a direct expression, ASC-assembly, and MSU-response experiment.
CP4 — Caspase-1¶
Mechanism: ASC speck recruits and activates caspase-1 via CARD-CARD interactions. In the canonical NLRP3 pathway, active caspase-1 cleaves pro-IL-1β, pro-IL-18, and gasdermin D. Caspase-1 is a major canonical executioner, not the only possible inflammatory or cell-death route in every system.
VX-765 (Belnacasan)¶
Mechanism: Prodrug → metabolized to VRT-043198 → potent, selective, reversible caspase-1 inhibitor. Blocks cleavage of pro-IL-1β, pro-IL-18, and gasdermin D simultaneously.
VX-765 is a prodrug of the caspase-1 inhibitor VRT-043198 and reached Phase 2a testing in epilepsy. That adjacent-indication record does not establish gout efficacy, current development status, or sufficiency of caspase-1 inhibition in a human flare.
VX-765 and Z-YVAD-FMK can serve as research comparators for caspase-1 inhibition. Availability does not establish gout relevance or clinical use.
Direct natural caspase-1 inhibitors are rare because caspase-1 activation depends on the physical ASC platform — it's a structural activation, not a simple enzyme-substrate interaction. But several compounds indirectly reduce caspase-1 activation:
Procyanidin B2 reduces MSU-induced caspase-1 cleavage and IL-1β secretion in macrophage experiments. The proposed link is reduced cathepsin-B signaling after lysosomal damage; human gout exposure is unestablished.
Epigallocatechin gallate (EGCG) suppresses caspase-1-related readouts in macrophages and has reported activity at CP1 and CP5. Food, extract, and assay exposures must be treated separately.
Berberine reduced caspase-1 transcript and protein readouts in cited experimental systems. This supports a CP4 assay readout, not a direct caspase-1 mechanism or multi-node efficacy claim.
Production chassis is downstream of the CP4 biological case. A caspase-1 payload should first demonstrate molecular identity, relevant exposure, direct pathway activity, and safety; only then should candidate production hosts be compared.
CP5 — IL-1β / IL-18 Output¶
Mechanism: The payload step. Mature IL-1β binds IL-1R1 on target cells → MyD88/IRAK → NF-κB → second wave of inflammation + neutrophil recruitment. CP5 splits into CP5a — receptor blockade (pharma biologics, the "off switch") and CP5b — active resolution via ALX/FPR2 (SPMs — the "resolve on command" switch, distinct from suppression).
CP5a — Receptor Blockade (Anakinra, Canakinumab, Rilonacept)¶
Anakinra (Kineret) and Canakinumab (Ilaris)¶
Mechanism: Recombinant IL-1 receptor antagonist (IL-1Ra) → competitive antagonist at IL-1R1 → blocks IL-1β AND IL-1α from binding receptor → shuts down all IL-1 signaling
Anakinra is a recombinant IL-1 receptor antagonist and a clinical comparator for CP5a. Its gout studies establish that IL-1 signaling is tractable; route and regimen belong to current clinical guidance rather than this mechanism map. See gout-clinical-pipeline.md.
Canakinumab (Ilaris): The current FDA label includes symptomatic treatment of adult gout flares when NSAIDs and colchicine are contraindicated, not tolerated, or inadequate and repeated corticosteroid courses are not appropriate. This supports IL-1β as a clinical target within that labeled population; it does not establish that another payload or route will reproduce the result. Regulatory label + Clinical Trial context; FDA prescribing information, revised 2024.
Topical cannabinoids as a CP2 hypothesis: CB2/NLRP3 and TRPV1 mechanisms have In Vitro and Animal Model support, but direct human gout-flare evidence is absent. This is a route-and-mechanism experiment, not an adjunct protocol. See cannabinoids-terpenes.md.
Suppression-plus-resolution interaction question: different nodes do not establish a useful interaction. Qualify each exact material and route alone, then use a prespecified factorial comparison. Exact SPMs and fatty-acid precursors are not interchangeable materials.
Exercise-related IL-6 can induce IL-1Ra and IL-10, but this is physiological context rather than an acute-flare protocol. A gout study would need to separate exercise timing, systemic cytokines, urate handling, and flare state.
EGCG suppresses IL-1β secretion and downstream signaling in experimental macrophage, chondrocyte, and synoviocyte systems. Human gout exposure and efficacy remain separate questions.
Direct SPM formulations and EPA/DHA precursors are distinct research materials. Identity, stability, exposure, and receptor engagement must be measured for the exact material.
CP5b — Active Resolution by Exact Mediators¶
Named SPMs have mediator- and system-specific receptors and outputs. This branch is kept separate from IL-1 receptor blockade, but “resolution” is not one transferable mechanism and a precursor is not a delivered mediator.
Direct MSU gout animal evidence: - RvD1 in MSU mouse gouty arthritis (Zaninelli 2022 Br J Pharmacol PMID 35716378) — intrathecal + IP RvD1 reduced mechanical hyperalgesia, IL-1β, leukocyte recruitment, NF-κB phosphorylation, ASC specks, and CGRP; revealed a nociceptor-macrophage resolution axis. (Animal Model.) - MaR1 in MSU peritonitis (Jiang 2023 Mol Med PMID 37996809) — MaR1 acts via Prdx5 upregulation + AMPK/Nrf2. (Animal Model.) - RvD2 in macrophage and zymosan systems (Lopategi 2018, PMID 29601102) — adjacent NLRP3/ASC evidence; not direct MSU-gout validation.
Complement-resolution conjecture: Schauer 2014 showed that high-density neutrophils can form aggNETs that degrade cytokines and chemokines in MSU-related systems (PMID 24784231). Whether exact RvD1 or MaR1 changes aggNET formation or proteolysis, whether C5a is a decisive bridge, and whether this loop controls human flare duration are untested. See the explicit Research Conjecture.
Candidate experimental inputs: exact RvD1, MaR1, or RvD2 preparations and separately defined EPA/DHA precursor configurations. Each requires exact-material identity, exposure, receptor/pathway readouts, and a gout-relevant comparator.
Deep dive: spm-resolution-pathway.md
CP6 — Neutrophil Amplification + Pyroptotic Exit¶
Mechanism: Renamed from "Gasdermin D" to acknowledge that the exit-route chokepoint is dominated by two cooperating amplification loops in gout: (a) 5-LOX → LTB4 → neutrophil chemotaxis (CP6a) and (b) GSDMD pore formation → pyroptotic IL-1β release → aggNET amplification (CP6b). Blocking either chokes the flare amplification loop.
CP6a — 5-LOX → LTB4 → Neutrophil Chemotaxis¶
Mechanism: 5-lipoxygenase converts arachidonic acid through LTA4 to LTB4, a neutrophil chemoattractant. Inhibiting this branch or changing substrate availability can alter neutrophil recruitment, but net gout effects require direct measurement.
Exploits at CP6a: - Quercetin — 300 nM IC50 against 5-LOX in the cited J Med Chem 1991 assay (PMID 2066989). This supplies an In Vitro CP6a hypothesis; it does not rank quercetin's mechanisms or establish gout activity. - AKBA (acetyl-11-keto-β-boswellic acid from Boswellia) — an unqualified 5-LOX lead pending primary-assay re-verification. Do not use it as an evidence-bearing comparator until exact material, assay, free exposure, and selectivity are pinned. - EPA substrate competition — loading EPA redirects 5-LOX away from arachidonic-acid-derived LTB4 and toward the resolving RvE1 series (connects CP6a to CP5b SPM resolution). - Salidroside (from Rhodiola rosea) — PMID 30265377 is retained as an MSU animal-study retrieval lead. Rehydrate the exact material, model, and measured mechanism before assigning an evidence tier or treating 5-LOX as established.
Zileuton is an approved 5-LOX inhibitor for asthma. The dated, unsnapshotted search summarized in its dossier did not establish a current registry census. It remains a CP6a research comparator: refresh the registries, then test gout-relevant target engagement, exposure, efficacy, and product-specific safety. See zileuton.md. Clinical Trial for asthma; Mechanistic Extrapolation for gout.
LTB4-mediated neutrophil recruitment is a distinct gout-relevant branch. Candidate inhibitors need human-relevant exposure, target engagement, and MSU-model validation; dietary occurrence or availability does not establish an intervention.
CP6b — Gasdermin D Pore Formation (Pyroptotic Exit)¶
Mechanism: Caspase-1 cleavage can release the GSDMD N-terminal fragment, which oligomerizes into membrane pores and enables pyroptotic cytokine release. Schauer 2014 reported anti-inflammatory functions for high-density aggNETs in MSU-related systems, but it did not establish a GSDMD → NET → aggNET sequence or show that GSDMD blockade preserves a resolution program. Those links require direct testing.
Disulfiram (Antabuse)¶
Mechanism: The primary study reported covalent modification of GSDMD Cys191 (human) / Cys192 (mouse), blocking pore formation while leaving upstream cleavage intact (PMID 32367036; In Vitro + Animal Model).
Disulfiram was reported to modify GSDMD Cys191 and prevent pore formation while leaving upstream cleavage intact. Gout-relevant exposure, selectivity, efficacy, and safety remain unestablished.
Disulfiram is FDA-approved for alcohol use disorder, not gout. Its GSDMD mechanism is a repurposing hypothesis that requires gout-relevant exposure, safety, and efficacy testing; the approval in another indication does not establish an access or prescribing path for this use.
DMF (Tecfidera) is FDA-approved for multiple sclerosis. A 2020 primary study reported DMF-mediated succination of gasdermin D at Cys191 and reduced GSDMD processing, oligomerization, pore formation, and pyroptosis (PMID 32820063; In Vitro + human pathway evidence outside gout).
In an MS context, DMF exposure was associated with lower IL-1β and GSDMD-N readouts. This is human target-pathway evidence in another indication, not gout efficacy or a regimen.
DMF is approved for multiple sclerosis, not gout. It hits GSDMD through a different mechanism and also activates Nrf2; gout translation remains a separate research question.
Necrosulfonamide (NSA) is a research comparator reported to modify human GSDMD Cys191 (PMID 30143556; In Vitro). This supports testing that residue as a vulnerability; it does not establish universal selectivity or that every Cys191-reactive compound blocks the pathway safely.
Lactoferrin — indirect CP6b hypothesis (Shan 2026 PMID 41524100). Shan et al. reported changes in mitophagy- and NLRP3/caspase-1/GSDMD-associated readouts in radiation-induced intestinal injury systems. This is an adjacent-model pathway lead, not evidence of direct GSDMD inhibition or MSU-gout activity. Evidence level: Animal Model + In Vitro for the adjacent injury model; Mechanistic Extrapolation for gout. See lactoferrin.md §4.1.
This map does not specify doses, timing, routes, or combinations. Those require compound-specific exposure and safety evidence and, where clinical care is involved, current clinical guidance.
1. Multi-chokepoint candidates¶
Interpretation: Multiple reported targets can justify a broader assay panel, but they do not establish higher efficacy, adequate exposure, or combination priority.
BHB (ketones): Reported to affect priming (CP1), K⁺ efflux (CP2), and ASC oligomerization (CP3). Human gout exposure and tissue-specific effects remain the relevant gates.
Berberine: Reported to suppress NF-κB/TLR4, alter inflammasome transcripts, and remodel gut microbiota. These effects require gout-specific and tissue-specific validation rather than a multi-use efficacy inference.
Oridonin: Reported covalent NLRP3 engagement and additional NF-κB/Nrf2-associated readouts in source-specific experimental systems. Each proposed node requires matched validation at measured exposure.
Dimethyl Fumarate: Nrf2 activator (CP1+CP2) AND gasdermin D succinator (CP6). Bridges the first and last chokepoints.
EGCG: Reported NF-κB-, caspase-1-, and IL-1β-associated readouts in source-specific experimental systems. Tea, extract, purified EGCG, and assay concentrations are not interchangeable.
Cross-Reference: Peptide Mechanisms
Several compounds overlap with the Peptides & Gout Addendum: BPC-157 (CP1 cytoprotection hypothesis), KPV (PepT1/NF-κB evidence with a gout-priming conjecture), and TB-500 (CP1/tissue-repair hypothesis). Node count does not rank efficacy. Each candidate needs human-relevant exposure, a gout-specific readout, and its own safety gate.
2. Accessible exposures requiring controlled comparison¶
Interpretation: Existing dietary or supplement exposure can serve as a measured covariate or comparator; it is not presumed beneficial.
BPC-157: macrophage cytoprotection in adjacent models is a hypothesis for an MSU assay, not evidence of reduced gout severity.
Fermented foods can contain spermidine, trehalose, and polyphenols. Their presence does not establish delivered exposure or CP2/CP3 target engagement; measure the compound and biological readout separately.
Koji baseline: traditional fermentation produces proteases and a mixture of metabolites. Any anti-inflammatory contribution must be measured against wild-type and inactive-payload controls; it is not assumed from fermentation alone.
3. Multi-payload delivery hypothesis¶
Interpretation: A multi-payload construct is considered only after each payload passes its biological gate and a combination demonstrates nonredundant benefit.
Candidate payload classes include:
- Uricase — dissolves uric acid (upstream of everything)
- KPV-like anti-inflammatory peptides — NF-κB suppression (CP1)
- Enhanced spermidine biosynthesis — autophagy activation (CP2/CP3)
- Nrf2-activating compounds — antioxidant defense (CP1/CP2)
Expression host is selected only after the payload's biological case is established. Each additional payload must improve measured activity without unacceptable expression, stability, exposure, safety, or manufacturing cost.
4. Cross-tissue NLRP3 hypothesis¶
Mechanism: NLRP3 inflammasome is central to both conditions
NLRP3 biology in intestinal and synovial contexts raises a cross-tissue question, but activity in one tissue cannot be assumed to translate to the other.
Berberine: antimicrobial, NF-κB, inflammasome, and microbiome effects must be separated experimentally; an adjacent indication does not establish a shared treatment.
KPV peptide: intestinal uptake and NF-κB effects in colitis models justify tissue-specific testing; they do not establish systemic gout efficacy.
Omega-3 SPMs: resolution biology is relevant in both intestinal and joint inflammation, but exposure and effect must be measured separately by tissue.
BHB/fasting: NLRP3 effects and urate-handling effects may differ by tissue and timing; systemic translation cannot be assumed from one cell context.
Spermidine and trehalose: autophagy-related observations define mechanistic probes; gut-barrier and joint-macrophage outcomes require separate validation.
Bottom line: cross-tissue overlap generates comparative experiments, not a shared household treatment stack.
5. Countervailing mechanisms and translation risks¶
Interpretation: A candidate can improve one node while worsening another. Direction, timing, tissue, and exposure must be tested together.
BHB illustrates the problem: ketones can compete with urate excretion while also affecting NLRP3. The net direction in gout cannot be inferred from inflammasome activity alone, and no engineered uricase assumption resolves that tradeoff. See bhb-ketones.md.
Disulfiram blocks a terminal pyroptosis mechanism in adjacent models, but it is not established as a gout drug. Repurposing requires gout-relevant exposure, safety, and efficacy evidence.
Colchicine supplies a useful multi-readout comparator: microtubule disruption can change neutrophil behavior and inflammasome-assembly readouts. Those mechanisms are source- and system-specific; the map does not reduce clinical efficacy to one pathway.
Autophagy is a mechanistic layer: spermidine, trehalose, fasting, and rapamycin affect autophagy-related pathways, but the relevant exposure, tissue effect, and gout outcome remain candidate-specific questions.
The crystal-dissolution window separates urate lowering from flare control. Established prophylaxis provides the clinical comparator; an investigational NLRP3 intervention must not be assumed necessary or effective merely because it targets a different node.
Quercetin has reported NF-κB-pathway, xanthine-oxidase, and 5-LOX activities. These measurements come from different assays and exposures; they do not establish simultaneous target engagement, a preferred formulation, or a combined clinical effect. In Vitro; source: NLRP3 inhibitor screen.
Chokepoint evidence audit¶
The table lists currently named leads and established-care comparators. A filled row does not establish biological coverage, and a blank or merged row does not prove an exploitable gap.
Evidence states:
- Clinical, gout — human gout intervention evidence for the named compound and scope
- Clinical, adjacent — human evidence in another indication; gout translation open
- Preclinical — animal or in-vitro evidence; human translation open
- Engineering hypothesis — construct or computational work exists; biological validation incomplete
- Research conjecture — grounded premises plus an explicitly untested leap and discriminating observation
| Chokepoint | Intervention | Evidence state | Reference |
|---|---|---|---|
| CP0 — Crystal-triggered C5a priming | Avacopan | Clinical, adjacent; gout use requires separate evidence | complement-c5a-gout.md |
| CP0 | DAF/CD55 SCR1-4; C1-INH | Engineering hypotheses | DAF owner: H05 (COMP-012 evidence artifact); C1-INH: c1-inh-protease-stability-ecn-computational.md |
| CP0 | Defined Houttuynia materials | Research conjecture grounded in exact-material complement or adjacent inflammatory evidence; no direct gout CP0 validation | Houttuynia evidence; complement evidence |
| CP1a — NF-κB priming | EGCG; theaflavins; thymulin | Preclinical, with material- and assay-specific evidence | egcg.md, theaflavins.md, thymulin.md |
| CP1a | KPV as an uptake/priming conjecture; lactoferrin as a separate adjacent-model lead | KPV has non-MSU intestinal-epithelial and Jurkat-cell In Vitro evidence; neither candidate has a direct MSU-gout CP1a result | kpv-peptide.md, lactoferrin.md |
| CP1+CP2 | Glucocorticoid-receptor signaling | Mechanistic evidence here is preclinical/observational; clinical gout comparator evidence for named glucocorticoids lives on the clinical pipeline | §"Glucocorticoid Receptor Signaling"; clinical pipeline |
| CP2/CP3 — activation and ASC assembly | Colchicine | Clinical, gout | colchicine.md |
| CP2/CP3 | BHB; theaflavins; oridonin; spermidine | Preclinical; exposure and human effect unresolved | linked dossiers above |
| CP4 — Caspase-1 | VX-765 | Clinical adjacent; direct gout evidence remains thin | nlrp3-inhibitor-screen.md |
| CP5a — IL-1 receptor/output | Anakinra; canakinumab; rilonacept | Clinical evidence is compound- and indication-specific | gout-clinical-pipeline.md |
| CP5a | Inhaled mRNA–IL-1Ra | Engineering hypothesis | chassis-pending-interventions.md |
| CP5b — SPM resolution | Exact RvD1 and MaR1 materials; EPA/DHA as a separate precursor hypothesis | Animal Model MSU evidence for the named mediators; precursor conversion, exposure, and gout effect unresolved | spm-resolution-pathway.md |
| CP6a — 5-LOX/LTB4 | Zileuton; quercetin; AKBA as an unqualified retrieval lead | Clinical adjacent for zileuton; source-pinned In Vitro evidence for quercetin; no retained evidence tier for AKBA | zileuton.md; nlrp3-inhibitor-screen.md |
| CP6b — GSDMD | Disulfiram; DMF | Clinical adjacent plus preclinical mechanism; gout effect unresolved | disulfiram.md |
Two evidence gaps the audit makes visible:
- CP4 — caspase-1: VX-765 lacks a gout indication, and other inherited candidates require source rehydration. Direct gout evidence is thin.
- CP5a — IL-1β receptor: clinical biologics provide the established comparator, while inhaled mRNA-IL-1RA remains an unvalidated delivery hypothesis.
What the audit confirms: the corpus contains leads at several nodes but uneven gout-specific evidence. Direct target engagement, tissue access, and relevant outcomes remain the decision criteria.
Use this table for: evidence-gap analysis and navigation to the owning evidence dossiers. Do not rank candidates by whether a production route is already available.
Candidate evidence gaps¶
These compounds illustrate distinct pathway mechanisms. Production feasibility does not rank them; gout-specific evidence, delivered exposure, safety, and a discriminating experiment do.
Ursolic acid: adjacent-model evidence¶
The current page does not retain a primary-source-pinned ursolic-acid claim that is strong enough to carry an evidence tier. Preserve it only as a retrieval lead: rehydrate the exact material and assay first, then decide whether an MSU experiment is justified. A source-qualified lead would still require target-engagement, exposure, viability, and assay-interference controls before any production question.
Quercetin: two mechanistic hypotheses¶
Mechanism: NF-κB inhibition (CP1) + xanthine oxidase inhibition (uric acid production blockade). Double life in inflammatory and metabolic domains.
Evidence: - The current source set supports quercetin as an In Vitro xanthine-oxidase and inflammatory-pathway lead in defined assays. - It does not support the inherited 70–80% IL-1β number or a source-verified quercetin gout-arthritis validation claim. - A direct MSU experiment must separate urate-production, inflammasome-pathway, assay-interference, and exposure effects.
Next gate: Separate the urate-production and inflammasome mechanisms under matched exposure; do not infer a combined clinical effect from pathway adjacency.
Carnosine: dual-mechanism animal signal¶
The current page does not retain the primary record needed to support its inherited ROS, NLRP3-pathway, URAT1, GLUT9, or serum-urate claims. Rehydrate the exact carnosine material, animal model, exposure, and readouts before treating it as evidence-bearing. If the record survives, the next gate is a prespecified experiment that separates urate handling from inflammasome function rather than assuming a dual mechanism.
Taurine: potassium-efflux hypothesis¶
The inherited taurine paragraph lacked a source-pinned primary record, so it carries no retained potassium-efflux, sepsis, cardiac-injury, or gout claim. Rehydrate those records before advancing the idea. If a premise survives, the discriminating gate is an exact-material MSU experiment measuring intracellular potassium, NLRP3 output, exposure, viability, and assay interference.
Kojic acid: direct NLRP3 evidence gap¶
The inherited kojic-acid paragraph lacked a source-pinned primary record, so this page retains neither an NF-κB result nor a direct-NLRP3 absence claim. A reproducible literature refresh must precede biological prioritization.
Next gate: Run an MSU-challenged macrophage assay with matched vehicle and viability controls, then measure ASC specks, caspase-1 cleavage, and IL-1β. A positive signal establishes a biological lead, not a chassis winner.
Combination decision rule¶
Do not infer synergy or require a multi-compound stack from separate single-agent mechanisms. Test individual candidates first; advance a combination only when a prespecified comparison demonstrates nonredundant benefit at measured exposure without an unacceptable safety signal.